Carbohydrate antigen 19-9 levels in early acute pancreatitis

There are many etiologic factors responsible for acute pancreatitis. Carbohydrate antigen 19-9 is a well-known tumor marker for gastrointestinal malignancies, especially pancreaticobiliary cancer. Carbohydrate antigen 19-9 levels also increase benign events such as cholestasis. Therefore, the purpose of this study is to retrospectively investigate the relationship between the underlying etiologies and carbohydrate antigen 19-9 levels in patients who were hospitalized due to acute pancreatitis. Materials and Methods: We retrospectively analyzed the data of 109 patients who had increased carbohydrate antigen 19-9 levels in the first 24 hours during hospitalization. Additionally, we divided the patients into two groups, namely biliary and nonbiliary, based on their recent diagnoses in the etiologies of acute pancreatitis. Results: We detected increased carbohydrate antigen 19-9 levels (more than 37 U/mL) in 63 (92%) of the patients in the biliary group, and in 8 (19%) of the patients in the non-biliary group (p

Akut pankreatitte karbonhidrat antijen 19-9 seviyeleri

Akut pankreatit için birçok etiyolojik faktör bulunmaktadır. Karbonhidrat antijeni 19-9, gastrointestinal malignitelerde, özellikle pankreatikobiliyer kanserde iyi bilinen tümör belirtecidir. Karbonhidrat antijeni 19-9 seviyeleri ayrıca kolestaz gibi iyi huylu hadiselerde de artış gösterir. Bu nedenle akut pankreatit nedeniyle hastanede yatan hastalarda altta yatan etiyolojiler ile karbonhidrat antijeni 19-9 düzeyleri arasındaki ilişkiyi retrospektif olarak araştırmayı amaçladık. Gereç ve Yöntem: Hastanede yatış sırasında ilk 24 saatte karbonhidrat antijeni 19-9 düzeyi bakılan 109 hastanın verilerini retrospektif olarak inceledik. Hastalar akut pankreatit etiyolojisindeki son tanılarına dayanarak biliyer ve non-biliyer olarak iki gruba ayrıldı. Bulgular: Biliyer gruptaki hastaların 63’ünde (%92), non-biliyer gruptaki hastaların 8’inde (%19) karbonhidrat antijeni 19-9 düzeyi 37 U/mL’den yüksek saptandı (p

PDF

___

1. Kaya E, Dervişoğlu A, Polat C. Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. World J Gastroenterol 2007;13:3090-4.

2. Kasap E, Akyıldız M, Tekin F, et al. Angiotensin-converting enzyme genotype and acute pancreatitis in Turkey. Balk J Med Genet (BJMG) 2009;12:39-44.

3. Cüre E, Basturk A, Şahin M, et al. The evaluation of tumor markers in acute pancreatitis. Turk J Cancer. 2007;37:11-5.

4. Al-Jiffry BO, Khayat S, Abdeen E, Hussain T, Yassin M. A scoring system for the prediction of choledocholithiasis: a prospective cohort study. Ann Saudi Med 2016;36:57-63.

5. Sherman JL, Shi EW, Ranasinghe NE, et al. Validation and improvement of a proposed scoring system to detect retained common bile duct stones in gallstone pancreatitis. Surgery 2015;157:1073-9.

6. Kim MS, Jeon TJ, Park JY, et al. Clinical interpretation of elevated CA 19-9 levels in obstructive jaundice following benign and malignant pancreatobiliary disease. Korean J Gastroenterol 2017;70:96- 102.

7. Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009;198:333-9.

8. Ong S, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008;53:3213-7.

9. Akimoto S, Banshodani M, Nishihara M, et al. Acute cholecystitis with significantly elevated levels of serum carbohydrate antigen 19- 9. Case Rep Gastroenterol 2016;10:410-6.

10. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9.

11. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223- 5.

12. Richter JM, Christensen MR, Rustgi AK, Silverstein MD. The clinical utility of the CA19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss: a cost-effectiveness analysis. Arch Intern Med 1989;149:2292-7.

13. Paganuzzi M, Onetto M, Marroni P, et al. CA 19‐9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988;61:2100-8.

14. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-7.

15. Katsanos KH, Kitsanou M, Christodoulou DK, Tsianos EV. High CA 19-9 levels in benign biliary tract diseases: report of four cases and review of the literature. Eur J Intern Med 2002;13:132-5.

16. Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA 19-9 not associated with malignancy. South Med J 2006;99:306-8.

17. Sanchez M, Gomes H, Marcus EN. Elevated CA 19-9 levels in a patient with Mirizzi syndrome: case report. South Med J 2006;99:160-4.

18. Marcouizos G, Ignatiadou E, Papanikolaou GE, et al. Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. Cases J 2009;2:6662.

19. Bertino G, Ardiri AM, Calvagno GS, et al. Carbohydrate 19.9 antigen serum levels in liver disease. Biomed Res Int 2013;2013:531640.

20. Shin JY, Yoo SJ, Park BM, et al. Extremely increased serum carbohydrate antigen 19-9 levels caused by new or resistant infections to previous antibiotics in chronic lung diseases. Tuberc Respir Dis (Seoul) 2013;75:125-7.

21. Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33.

22. Hong JY, Jang SH, Kim SY, et al. Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease. Braz J Infect Dis 2016;20:26-32.

23. Videhult P, Sandblom G, Rudberg C, Rasmussen IC. Are liver function tests, pancreatitis and cholecystitis predictors of common bile duct stones? Results of a prospective, population-based, cohort study of 1171 patients undergoing cholecystectomy. HPB (Oxford) 2011;13:519-27.

24. Kim H-J, Kim M-H, Myung S-J, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6.

25. Goonetilleke K, Siriwardena A. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70.

26. Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001;181:16-9.

27. Stiksma J, Grootendorst DC, van der Linden PWG. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. Clin Colorectal Cancer 2014;13:239-44.

28. Scarpa M, Noaro G, Saadeh L, et al. Esophageal cancer management: preoperative CA19. 9 and CEA serum levels may identify occult advanced adenocarcinoma. World J Surg 2015;39:424-32.

29. Song Y-x, Huang X-z, Gao P, et al. Clinicopathologic and prognostic value of serum carbohydrate antigen 19-9 in gastric cancer: a meta- analysis. Dis Markers 2015;2015:549843.

30. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA 19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009;8:620-6.

31. Teng D, Wu K, Sun Y, et al. Significant increased CA 19-9 levels in acute pancreatitis patients predicts the presence of pancreatic cancer. Oncotarget 2018;9:12745-53.

32. Roberts SE, Morrison-Rees S, John A, et al. The incidence and aetiology of acute pancreatitis across Europe. Pancreatology 2017;17:155-65.